Influenza A Market Overview
DelveInsight projects strong growth in the 7MM Influenza A market through 2034, led by the US. The report analyzes key patient segments—vaccinated populations, vaccine failures, positive cases, and strain-specific cases—and profiles major companies including Roche, BioCryst Pharmaceuticals, Seqirus, Moderna, Cidara Therapeutics, GlaxoSmithKline, Cocrystal Pharma, and others advancing next-generation antivirals and vaccines such as mRNA-1010, CD388, GSK4382276A, and CC-42344, supported by recent regulatory filings and Phase III successes.
Key Takeaways
- Market Growth: Significant expansion expected through 2034, with the US maintaining the largest market share.
- Patient Landscape: Comprehensive segmentation across vaccinated cohorts, vaccine failure populations, strain-specific cases, and total influenza A–positive cases across the 7MM.
- Leading Companies: Roche, BioCryst, Seqirus, Moderna, Cidara Therapeutics, GSK, Cocrystal Pharma, and others advancing innovative influenza A therapies.
- Pipeline Highlights: Major assets include mRNA-1010, CD388, GSK4382276A, CC-42344, and additional candidates targeting multiple antiviral mechanisms.
Recent Developments
- Cidara to present new CD388 data at ICAR 2025.
- FDA releases updated strain-selection recommendations for 2025–2026 vaccines.
- FDA approves Fluad, the first MF59-adjuvanted seasonal vaccine for adults ≥65.
- FDA expands Flublok’s indication to children ≥9 years.
- Osivax secures €10M Series B funding for its broad-spectrum vaccine OVX836.
- Roche files XOFLUZA for infants 0–1 year and reports Phase III success in reducing transmission.
Discover more recent advancements in the Influenza A landscape @ Influenza A Recent Developments.
Market Dynamics
The Influenza A market is shaped by continual viral evolution, seasonal and pandemic threats, and high vaccine failure rates. Established antivirals—such as XOFLUZA, TAMIFLU, RELENZA, and RAPIVAB—anchor current treatment, while next-generation mechanisms like PB2 inhibitors and Drug-Fc conjugates drive innovation. Universal vaccine strategies, long-acting prophylaxis, and rapid diagnostics represent emerging opportunities toward 2034.
Download the Influenza A Market report to understand which factors are driving the therapeutic market @ Influenza A Market Trends.
Epidemiology Overview
Across the 7MM, vaccination patterns and strain-specific prevalence shape therapeutic demand. Adults aged 18–49 represent the largest vaccinated pool, while pregnant women remain the least vaccinated. The US maintains the highest disease burden; Germany leads within EU4+UK. In 2024, A(H1N1)pdm09 dominated European strain distribution. Overall positive cases are projected to rise steadily through 2034.
Discover evolving trends in the Influenza A epidemiology forecasts @ Influenza A Patient Pool Analysis.
Competitive Landscape and Key Companies
Influenza A treatment features both established antivirals and an expanding pipeline. Roche, BioCryst, Seqirus, Moderna, Cidara Therapeutics, GSK, and Cocrystal Pharma lead development across multiple modalities—from mRNA vaccines to PB2 inhibitors and universal prophylactic candidates like CD388, which has Fast Track designation. Pipeline activity remains strong across Phase I–III trials, supported by strategic partnerships, licensing agreements, and government procurement initiatives.
Delve deeper into the major and specialised companies in the Influenza A market @ Influenza A Competitive Landscape.
Conclusion
The Influenza A market is positioned for substantial growth through 2034, supported by accelerating innovation in vaccines, antivirals, and long-acting prophylactic therapies. With increasing disease burden, evolving strains, and strong industry investment, the market is poised to address major unmet needs and deliver transformative advances in influenza prevention and treatment.
Scope of the Influenza A Market Report
- Executive summary and detailed overview of influenza A, including causes, symptoms, pathogenesis, and current therapies
- Historical and forecasted market size, key assumptions, and therapy share analyses across the 7MM
- Epidemiology segmentation including vaccinated populations, vaccine failures, positive cases, and strain-specific data
- Pipeline review across development phases and therapeutic modalities
- Competitive landscape analysis with cross-competition insights
- Market access, treatment practices, unmet needs, and opportunity assessment
- Drug uptake projections and market drivers through 2034
- Qualitative assessments including SWOT and conjoint analysis
Table of Contents
- Key Insights
- Executive Summary of Influenza A
- Competitive Intelligence Analysis for Influenza A
- Influenza A Market Overview at a Glance
- Influenza A: Disease Background and Overview
- Influenza A Patient Journey
- Influenza A Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Influenza A Unmet Needs
- Key Endpoints of Influenza A Treatment
- Influenza A Marketed Products
- Influenza A Emerging Therapies
- Influenza A: Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Influenza A
- KOL Views
- Influenza A Market Drivers
- Influenza A Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
